Cargando…
Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis
AIMS: This subgroup analysis of the ENTRUST-AF PCI trial (ClinicalTrials.gov Identifier: NCT02866175; Date of registration: August 2016) evaluated type of AF, and CHA(2)DS(2)-VASc score parameters as predictors for clinical outcome. METHODS: Patients were randomly assigned after percutaneous coronar...
Autores principales: | Goette, Andreas, Eckardt, Lars, Valgimigli, Marco, Lewalter, Thorsten, Laeis, Petra, Reimitz, Paul-Egbert, Smolnik, Rüdiger, Zierhut, Wolfgang, Tijssen, Jan G., Vranckx, Pascal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166657/ https://www.ncbi.nlm.nih.gov/pubmed/33098470 http://dx.doi.org/10.1007/s00392-020-01760-4 |
Ejemplares similares
-
Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial
por: Vranckx, Pascal, et al.
Publicado: (2020) -
Corrigendum to: Edoxaban in AF patients with PCI by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial
Publicado: (2020) -
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
por: Hohnloser, Stefan H, et al.
Publicado: (2019) -
Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial
por: Hohnloser, Stefan H, et al.
Publicado: (2020) -
Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
por: De Caterina, Raffaele, et al.
Publicado: (2019)